Jim Simons
ADMA icon

Jim Simons’s ADMA Biologics ADMA Stock Holding History

Jim Simons’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.4M Sell
1,262,634
-269,987
-18% -$4.26M 0.02% 911
2025
Q4 		$28M Sell
1,532,621
-1,237,821
-45% -$20.9M 0.04% 475
2025
Q3 		$40.6M Sell
2,770,442
-375,611
-12% -$6.44M 0.05% 428
2025
Q2 		$57.3M Sell
3,146,053
-402,935
-11% -$8.22M 0.08% 292
2025
Q1 		$70.4M Sell
3,548,988
-220,900
-6% -$3.82M 0.11% 231
2024
Q4 		$64.7M Buy
3,769,888
+102,692
+3% +$1.93M 0.1% 244
2024
Q3 		$73.3M Buy
3,667,196
+1,085,061
+42% +$16.9M 0.11% 217
2024
Q2 		$28.9M Buy
2,582,135
+575,100
+29% +$4.82M 0.05% 453
2024
Q1 		$13.2M Buy
2,007,035
+949,100
+90% +$5.19M 0.02% 846
2023
Q4 		$4.78M Sell
1,057,935
-338,620
-24% -$1.25M 0.01% 1380
2023
Q3 		$5M Buy
1,396,555
+182,820
+15% +$704K 0.01% 1315
2023
Q2 		$4.48M Buy
1,213,735
+240,500
+25% +$891K 0.01% 1484
2023
Q1 		$3.22M Buy
973,235
+277,300
+40% +$959K ﹤0.01% 1735
2022
Q4 		$2.7M Buy
695,935
+57,535
+9% +$177K ﹤0.01% 1894
2022
Q3 		$1.55M Sell
638,400
-87,100
-12% -$209K ﹤0.01% 2202
2022
Q2 		$1.44M Buy
725,500
+198,800
+38% +$391K ﹤0.01% 2446
2022
Q1 		$964K Buy
526,700
+177,800
+51% +$277K ﹤0.01% 2748
2021
Q4 		$492K Buy
348,900
+113,900
+48% +$150K ﹤0.01% 3082
2021
Q3 		$266K Buy
235,000
+59,374
+34% +$83.2K ﹤0.01% 3117
2021
Q2 		$281K Buy
+175,626
New +$309K ﹤0.01% 3166
2018
Q4 		– Sell
-188,300
Closed -$1.17M – 3349
2018
Q3 		$1.17M Buy
188,300
+159,100
+545% +$916K ﹤0.01% 2538
2018
Q2 		$132K Buy
+29,200
New +$146K ﹤0.01% 3121
2017
Q4 		– Sell
-20,300
Closed -$63K – 3307
2017
Q3 		$63K Buy
20,300
+9,000
+80% +$30K ﹤0.01% 3117
2017
Q2 		$42K Buy
+11,300
New +$45.4K ﹤0.01% 3131

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Jim Simons's ADMA Position: Q1 2026 in Review

Jim Simons reduced its ADMA Biologics (ADMA) stake by 18% in Q1 2026, selling an estimated $4.26M and leaving 1,262,634 shares worth $11.4M. The position accounts for 0.02% of the portfolio, ranked #911.

Jim Simons first reported a position in ADMA in Q2 2017 and has held it in 24 quarters since. The position peaked at $73.3M in Q3 2024. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Jim Simons held 1,262,634 shares of ADMA Biologics worth $11.4M as of Q1 2026.
  • Jim Simons sold 269,987 ADMA Biologics shares in Q1 2026, an estimated $4.26M.
  • ADMA Biologics made up 0.02% of Jim Simons's portfolio in Q1 2026, its #911 holding.
  • Jim Simons first reported a position in ADMA Biologics in Q2 2017 and has held it in 24 quarters since.
  • Jim Simons's ADMA Biologics position peaked at $73.3M in Q3 2024.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.